Invex Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Other Revenue	0.05	0.23	1.21	0.46	0.18
Revenue	0.05	0.23	1.21	0.46	0.18
Revenue Growth	-79.56%	-81.10%	164.06%	151.90%	-
Gross Profit	0.05	0.23	1.21	0.46	0.18
Selling, General & Admin	1.02	0.72	1.17	1.12	0.9
Research & Development	0.52	0.2	2.04	7.4	2.96
Operating Expenses	1.54	0.94	3.35	9.01	4.22
Operating Income	-1.5	-0.71	-2.13	-8.55	-4.03
Interest & Investment Income	0.13	0.23	0.49	0.8	0.08
Other Non Operating Income (Expenses)	0.02	-	-	-	-
EBT Excluding Unusual Items	-1.35	-0.48	-1.64	-7.75	-3.95
Pretax Income	-1.35	-0.48	-1.64	-7.75	-3.95
Net Income	-1.35	-0.48	-1.64	-7.75	-3.95
Net Income to Common	-1.35	-0.48	-1.64	-7.75	-3.95
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	75	76	75	75	75
Shares Outstanding (Diluted)	75	76	75	75	75
Shares Change	-0.74%	0.51%	0.19%	0.02%	0.03%
EPS (Basic)	-0.02	-0.01	-0.02	-0.10	-0.05
EPS (Diluted)	-0.02	-0.01	-0.02	-0.10	-0.05
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-3198.22%	-309.63%	-176.00%	-1861.73%	-2212.89%
Profit Margin	-2888.04%	-208.16%	-135.43%	-1688.11%	-2169.06%
EBIT	-1.5	-0.71	-2.13	-8.55	-4.03
EBIT Margin	-	-	-176.00%	-	-